In contrast, the current study included subgroup analyses for the different indicators including RFS, PFS, OS, and DSS/CSS, allowing more thorough insights into the relationships between p16 expression and the prognostic and clinicopathological parameters in bladder cancer patients. Here, CDKN2A is linked to urinary bladder carcinoma.